by Gemma Escarré,
Esteve and the Neuropharmacology Group of Pompeu Fabra University (UPF) are beginning the Ribopain project to identify and validate new therapeutic targets for neuropathic pain. The initiative has received funding in the Retos 2017 call by the Spanish Ministry of Science, Innovation and Universities.
Its principal investigators will be José Miguel Vela, Director of Drug Discovery & Preclinical Development at Esteve, and Rafael Maldonado and Miquel Martin of UPF.
19% of the adult European population suffers from moderate to severe pain. Neuropathic pain, which is the most refractory to treatment, appears as a result of a traumatic or degenerative lesion to the nerve structures with no obvious stimulus. This pain is difficult to palliate with conventional therapies and can become severe and disabling. Thus today, the search for therapeutic solutions is an unmet medical need and a health challenge.